Bristol-Myers Squibb Compnay

Donald R O'Boyle, Ii

Nicholas A Meanwell

Makonen Belema

Julie A Lemm

John F Kadow

Piyasena Hewawasam

Lawrence B Snyder

Michael H Serrano-Wu

Omar D Lopez

Denis R St Laurent

Van N Nguyen

Fukang Yang

Alan Xiangdong Wang

Yuping Qiu

Yong Tu

Ningning Xu

John E Leet

Xuejie Yang

Ramesh Kakarla

Samayamunthula Venkata Satya Arun Kumar Gupta

Ying-Kai Wang

Pothukanuri Srinivasu

Robert A Fridell

Jin-Hua Sun

Indasi Gopi Kumar

Ponugupati Suresh Kumar

Chunfu Wang

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.

Inhibitors of HCV replication

Growing community of inventors

Killingworth, CT, United States of America

Donald R O'Boyle, Ii